Oncodesign

French biotechnology company at Dijon, founded in 1995, which worked for many years as a contract research organisation in oncology pharmacology before selling that business in 2022 and continuing as Oncodesign Precision Medicine. Discovers small molecule medicines using its Nanocyclix kinase inhibitor chemistry and its own artificial intelligence and biological data platform, runs programmes in oncology and in neurological and inflammatory disease, and works with pharmaceutical partners on joint discovery projects.